{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-020102","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.941009+00:00","generated_at":"2026-05-19T13:14:31.815629+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Genprex secures $12.5M equity line with Lincoln Park; provides clinical trial updates","bullets":["Entered purchase agreement for up to $12.5M in common stock; issued 1,186,859 commitment shares to Lincoln Park.","Acclaim-1 Phase 2a expansion targets ~33 patients; interim analysis of first 19 expected Q1 2026, top-line in H1 2026.","Acclaim-3 Phase 2 expansion plans ~50 patients; futility analysis after 25 patients expected Q1 2026.","Both Acclaim-1 and Acclaim-3 have FDA Fast Track designation; Acclaim-3 also has Orphan Drug Designation.","Proceeds from Lincoln Park sales to be used for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-020102","json":"https://secwatch.observer/filing/0001437749-25-020102.json","markdown":"https://secwatch.observer/filing/0001437749-25-020102.md","text":"https://secwatch.observer/filing/0001437749-25-020102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/0001437749-25-020102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/gnpx20250606c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T13:14:31.815629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}